BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alltracel Pharmaceuticals Plc Announces M-doc(TM) Co-Brand Partnership Agreement With 3M


10/19/2005 5:09:53 PM

PARIS, and DUBLIN, Ireland, Feb. 3 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (AIM: AP.L), the biopharmaceutical R&D company specializing in medical devices and compounds and owner of the stops-bleeding m-doc(TM) first-aid ingredient brand and SEAL-ON(TM) the consumer first-aid brand featuring stops-bleeding as standard, is pleased to announce a material supply, technology transfer and co-brand partnership program with the Health Care division of 3M , the global diversified technology company. The agreement, effective February 01, will allow 3M to launch its first three stops bleeding products featuring Alltracel's m-doc(TM) first-aid ingredient brand inside 3M 's NEXCARE(TM) first aid brand name in 28 countries in Europe and the Middle East.

3M will initially launch m-doc(TM) co-branded plasters/bandages, followed by nasal sponges and wound spray products, under the NEXCARE(TM) first aid brand umbrella, with shipments commencing this quarter, Q1 2004.

Donal O'Brien Alltracel's Chief Operating Officer (COO) commented:

"We are particularly delighted that 3M, a corporation of recognised global stature and enviable reputation for innovation in the healthcare markets and other sectors, is the latest company to join the m-doc(TM) co-brand partnership program in Europe.

"As well as the significant vote of confidence in the m-doc(TM) technology platform, the 3M agreement is significant from an ongoing recurring revenue perspective and is expected to generate more than half a million euro this first year, on the basis of these three products."

Noel Toolan Alltracel's Chief Marketing Officer said:

The NEXCARE brand endorsement of the m-doc(TM) stops bleeding technology platform is another significant milestone for the m-doc(TM) brand and its progress in becoming a standard in the consumer first aid market. This agreement will mean that the benefit of m-doc(TM) stops bleeding technology will now be available in all European markets in partnership with more than 30 respected consumer brands.

About Alltracel: (http://www.alltracel.com/) Alltracel Pharmaceuticals PLC is an innovative bio-pharmaceutical company specializing in medical devices and compounds, which control bleeding and accelerate the natural healing process efficiently. Headquartered in Dublin, Ireland and with an R&D subsidiary in the Czech Republic, Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.

m-doc(TM) (Micro Dispersed Oxidized Cellulose; (http://www.m-doc.com/) is the end product of Alltracel's patented process, applied to cotton in the form of raw cellulose and is proven as an effective and efficient haemostatic (blood-stopping) agent in wound care devices. The route-to-market is via licensed trademark and ingredient supply agreements with existing recognized wound care brands. SEAL-ON(TM) (http://www.sealonrange.com/) is the world's first first-aid treatment brand featuring stops bleeding m-doc(TM) as standard. The

SEAL-ON(TM) range features six different product delivery systems -- including sprays, nasal plugs, patches and plasters -- each designed for specific usage occasions and all containing the stops-bleeding m-doc(TM) ingredient brand.

R&D on the core -- polysaccharides manipulation -- technology platform has confirmed significant and exciting potential applications beyond the Wound- care market, primarily in the Dermatological and Nutritional Foods market sectors.

About 3M: 3M (http://www.3m.com/), the globally diversified technology company operates in more than 200 countries focusing on the consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation sectors. The healthcare division is 3M's largest business unit and with 2003 revenue of almost $4 billion is in itself one of the world's largest healthcare companies, with a particular reputation for innovation. NEXCARE is 3M's international flagship consumer first-aid brand and is sold in all 3M's major markets.

Alltracel Pharmaceuticals PLC

CONTACT: Dublin: Denise Cronin of Alltracel, +353-1-235-2162, orpress@alltracel.com; or London: Debbie Ardern-Jones, +44-207-269-7110, or NewYork: Tiernan Cavanna, +1-212-850-5600, both of Financial Dynamics, forAlltracel



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES